Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shuganyiyang Capsules is a Traditional Chinese Medicine (TCM) product developed and marketed by Guizhou Yibai Pharmaceutical. It is primarily indicated for the treatment of erectile dysfunction (ED) associated with liver qi stagnation and kidney deficiency, according to TCM principles. The formulation is a complex mixture of herbal ingredients, including *Tribulus terrestris*, *Epimedium*, *Cuscuta chinensis*, and *Morinda officinalis*. Pharmacological studies suggest that the drug works by enhancing the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) signaling pathway, which promotes the relaxation of penile corpus cavernosum smooth muscle and improves blood flow. It is widely utilized in China as a standard therapeutic option for male sexual dysfunction and has been included in various clinical guidelines for the treatment of ED.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shuganyiyang capsules.